Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
City of Hope Medical Center, Duarte, California, United States
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Centre Léon Bérard, Lyon, France
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
The Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Duke University, Durham, North Carolina, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
University of California San Diego, La Jolla, California, United States
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Northwestern University, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.